An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line

Launched by CHINANORM · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical study is looking at how well the CeraVe skin care products work to improve facial acne, ranging from mild to severe cases. The study will observe participants’ skin health before and after using CeraVe products alongside their current acne treatments, with doctors checking the skin and participants sharing their thoughts on how the products affect their skin and overall quality of life. The goal is to see if CeraVe products are safe, well-tolerated, and helpful in managing acne symptoms over an 8-week period.

People who may join this study are Chinese males and females aged 13 or older who have mild, moderate, or severe acne and have started acne treatment within the past three months. Participants should be generally healthy and not have other serious medical conditions or skin issues that could affect the study. The study will include about 240 people, with skin checks and feedback collected at the start, 4 weeks, and 8 weeks. If you join, you’ll be asked to use the CeraVe products while continuing your acne medication and attend three clinic visits for skin assessments and to share your experience. This study is not yet recruiting, but it offers a chance to learn if these skincare products might help improve acne in real-life use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chinese males and females, age eligible greater than or equal to 13 years old;
• • Be in good health and free from any other chronic disease or disease under treatment;
• * Be judged by a dermatologist at the Baseline visit:
• • Mild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA)11,12 (Mild - Grade 1 or Grade 2) Acne Grading Scale (GEA) - Scale 1 or 2, Moderate - Scale 3, Severe - Scale 4 or above);
• • Initiation of acne treatment within the last 3 months with medications that include, but are not limited to, the following
• • 1. Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, 0.1% adapalene/BPO. b) Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, adapalene 0.3% adapalene/BPO, retinoic acid/clindamycin, BPO/clindamycin;
• • 2. Oral medications: antibiotics, spironolactone, isotretinoin, etc; If Global Evaluation Acne Grading Scale (GEA) classification is ≥2, continuous use of the above medications for at least 2 weeks prior to the baseline visit is required.
• • If the Global Evaluation Acne Grading Scale (GEA) is ≥2, acne treatment with the above medications should be continued for at least 2 weeks before the baseline visit; If oral medication is used, acne treatment should be continued for at least 4 weeks prior to the baseline visit.
• Exclusion Criteria:
• • Adult female study participants who intend to plan a pregnancy, or who are pregnant, breastfeeding, within 6 months of delivery, or who are unwilling to take the necessary precautions to avoid pregnancy;
• • Study participants who are currently enrolled in another clinical study or have been enrolled in another clinical study within 3 months;
• • Study participants who have undergone physical, chemical, or cosmetic surgery within 3 months prior to enrollment;
• • Systemic diseases with severe organ damage, cardiovascular diseases, liver or kidney dysfunction, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and psychiatric disorders, or other diseases that require topical or systemic use of medications or treatments that have an effect on acne;
• • The study site is associated with other skin disorders (atopic dermatitis, rosacea, rosacea, eczema, etc.) or the presence of other skin conditions that interfere with evaluation (birthmarks, scarring, etc.);
• • Participants in the study have a history of allergic contact dermatitis caused by cleansers (facial cleansers)/moisturizers;
• • History of allergy or severe allergy to the products (Sensitive Skin products) and related ingredients provided in the study;
• • Study participants who are unable to follow compliance requirements, or who are known to be unable to attend visits on time, or who are unwilling to comply with the study protocol arrangements for the duration of the study;
• • Any clinical presentation or other illness in the required observation area that, in the opinion of the investigator, may affect the study product assessment or results.
• • Study participants had received medical aesthetic treatments (including but not limited to photofacial type treatments, fruit acid resurfacing, etc.) within 3 months prior to enrollment.